

**The Exocyclic Olefin Geometry Control via Ireland-Claisen
Rearrangement: Stereoselective Total Syntheses of Barmumycin and
Limazepine E**

Gints Smits and Ronalds Zemribo*

Latvian Institute of Organic Synthesis, Aizkraukles 21, LV-1006, Riga, Latvia

ronalds@osi.lv

TABLE OF CONTENTS

General Experimental Methods	S-3
Experimental Procedures.....	S-4
(<i>S</i>)- <i>Tert</i> -Butyl 2-((3-hydroxy-2-methylenebutyl) (4-methoxybenzyl)amino) acetate (10)	S-4
(<i>S</i>)-2-((3-hydroxy-2-methylenebutyl)(4-methoxybenzyl)amino)acetic acid 2,2,2- trifluoroacetic acid salt (SI-1).....	S-4
(<i>S</i>)-4-(4-Methoxybenzyl)-7-methyl-6-methylene-1,4- oxazepan-2-one (11)	S-5
General procedure for Ireland – Claisen rearrangement of (11).....	S-5
(<i>S,E</i>)-methyl 4-ethylidene-1-(4-methoxybenzyl)pyrrolidine-2- carboxylate (14).....	S-6
(<i>S,E</i>)-methyl 4-ethylidenepyrrolidine-2-carboxylate hydrochloride (SI-2).....	S-7
(<i>S,E</i>)-Methyl 4-ethylidene-1-(4-hydroxy-3-methoxybenzoyl)pyrrolidine- 2-carboxylate (SI-3)	S-7
Barmumycin 1	S-8
Comparison of Barmumycin to the literature NMR data.....	S-9


Methyl 2-amino-3-hydroxy-4-methoxybenzoate SI-4	S-9
Comparison of SI-4 to the literature NMR data	S-10
2-Amino-3-hydroxy-4-methoxybenzoic acid SI-5	S-10
(<i>S,E</i>)-2-Ethylidene-9-hydroxy-8-methoxy-2,3-dihydro-1 <i>H</i> -benzo[<i>e</i>]pyrrolo[1,2- <i>a</i>][1,4]diazepine-5,11(10 <i>H</i> ,11 <i>aH</i>)-dione 17	S-11
(9 <i>aS,E</i>)-8-ethylidene-3-methoxy-1-phenyl-7,8,9,9 <i>a</i> -tetrahydro-1 <i>H</i> -2-oxa-6 <i>a</i> ,10 <i>a</i> -diazabenz[<i>cd</i>]cyclopenta[<i>g</i>]azulene-6,10-dione 18	S-11
Limazepine E 4	S-12
Comparison of Limazepine E to literature NMR data	S-13
(<i>S,E</i>)-2-Ethylidene-2,3-dihydro-1 <i>H</i> -benzo[<i>e</i>]pyrrolo[1,2- <i>a</i>][1,4]diazepine-5,11(10 <i>H</i> ,11 <i>aH</i>)-dione 19	S-13
(<i>S</i>)-1 <i>H</i> -Benzo[<i>e</i>]pyrrolo[1,2- <i>a</i>][1,4]diazepine-2,5,11(3 <i>H</i> ,10 <i>H</i> ,11 <i>aH</i>)-trione 20	S-14
Comparison of 20 literature NMR data	S-15
NMR spectra	S-16

General Experimental Methods

Reagents and starting materials were obtained from commercial sources and used as received. The solvents were purified and dried by standard procedures prior to use; petroleum ether of boiling range 60–80 °C was used. Flash chromatography was carried out using Merck Kieselgel (230–400 mesh). Thin-layer chromatography was performed on Merck Kieselgel 60F254. NMR spectra were recorded on Varian Mercury (400 MHz) and Varian Unity Inova (600 MHz) spectrometers. Chemical shift values are referenced against residual proton in the deuterated solvents, multiplicity (s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet, br = broad). Infrared spectra were recorded in the range 4000-600 cm^{-1} as a film. HRMS were obtained on a Micromass AutoSpec Ultima Magnetic sector mass spectrometer. Optical rotations were measured using a Perkin Elmer 141 polarimeter. Melting points were determined using a Stanford Research System MPA100 Automated Melting Point Apparatus and were uncorrected.


Experimental Procedures

(S)-Tert-Butyl 2-((3-hydroxy-2-methylenebutyl) (4-methoxybenzyl)amino)acetate **10**




To a stirred solution of *tert*-butyl 2-((4-methoxybenzyl)amino)acetate (18.627 g, 0.074 mmol, 1.5 eq) and DIPEA (12.772 g, 0.099 mmol, 2 eq) in 50 mL of THF was dropwise added a solution of **9** (8.154 g, 0.049 mmol, 1 eq) in 20 mL of THF and the obtained solution was stirred for 16 h. The reaction mixture was diluted with DCM and saturated aqueous sodium bicarbonate solution, and twice extracted with DCM. The combined organic layers were dried over anhydrous Na₂SO₄, filtered and concentrated *in vacuo*. The residue was purified by flash column chromatography (Pet:EtOAc 9:1 – 2:1). The title compound was isolated as a yellow oil (11.270 g, 68%). ¹H NMR (400MHz; CDCl₃): δ 7.24 (2H, d, *J*=8.6 Hz), 6.86 (2H, d, *J*=8.6 Hz), 5.23 (1H, br s), 5.07 (1H, s), 4.94 (1H, s), 4.35 (1H, q, *J*=6.2 Hz), 3.79 (3H, s), 3.64 (2H, AB m), 3.42 (1H, d, *J*=12.5 Hz), 3.16 (1H, d, *J*=12.5 Hz), 3.15 (2H, AB m), 1.45 (9H, s), 1.24 (3H, d, *J*=6.2 Hz). ¹³C NMR (100MHz, CDCl₃): δ 170.35, 158.98, 147.81, 130.46, 129.63, 114.30, 113.82, 81.38, 70.50, 58.33, 57.57, 55.22, 54.49, 28.11, 21.68. HRMS-ESI (*m/z*): [*M* + H] calculated for C₁₉H₃₀NO₄, 336.2175; found 336.2182. IR (ν_{max}, film): 3442, 2977, 2933, 2836, 1733, 1612, 1513, 1301, 1157 cm⁻¹. [α]_D²⁵ = -0.07° (c = 1, CHCl₃).

(S)-2-((3-Hydroxy-2-methylenebutyl)(4-methoxybenzyl)amino)acetic acid 2,2,2-trifluoroacetic acid salt **SI-1**



To a stirred solution of **10** (4.000 g, 9.534 mmol) in 30 mL of DCM was added 10 mL of TFA. The mixture was stirred for 4 h, as color changed to black. The volatiles were removed *in vacuo* and the residue was used in the next step without further purification.

(S)-4-(4-Methoxybenzyl)-7-methyl-6-methylene-1,4-oxazepan-2-one 11



To a stirred solution of **SI-1** (8.654 g, 22.000 mmol, 1 eq) in 170 mL of DCM were added 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (10.544 g, 191.71 mmol, 2.5 eq), 1-hydroxybenzotriazole hydrate (7.432 g, 55.000 mmol, 2.5 eq) and *N,N*-diisopropylethylamine (11.374 g, 88.000 mmol, 4 eq). The obtained slurry was stirred for 15 h. The reaction mixture was diluted with saturated aqueous sodium bicarbonate solution, and extracted twice with DCM. The combined organic layers were dried over anhydrous Na₂SO₄, filtered and concentrated *in vacuo*. The residue was purified by flash column chromatography (Pet:EtOAc 2:1). The title compound was isolated as a yellow solid (4.320 g, 75%). ¹H NMR (400MHz; CDCl₃): δ 7.20 (2H, d, *J*=8,2 Hz), 6.85 (2H, d, *J*=8,2 Hz), 5.39 (1H, s), 5.12 (1H, s), 5.02 (1H, q, *J*=6.6 Hz), 3.81 (1H, d, *J*=16.0 Hz), 3.79 (3H, s), 3.58 (1H, d, *J*=16.0 Hz), 3.55 (2H, AB m), 3.40 (2H, AB m), 1.54 (3H, d, *J*=6.6 Hz). ¹³C NMR (100MHz, CDCl₃): δ 172.19, 158.94, 141.46, 130.09, 129.37, 116.80, 113.79, 75.54, 60.30, 57.51, 56.72, 55.21, 18.40. HRMS-ESI (*m/z*): [*M* + *H*] calculated for C₁₅H₂₀NO₃, 262.1443; found 262.1438. IR (*v*_{max}, film): 2985, 2943, 1729, 1611, 1513, 1246, 1028 cm⁻¹. [*α*]_D²⁵ = -64.32° (*c* = 0.82, CH₂Cl₂). **m.p.** 88 – 90°C.

General procedure for Ireland – Claisen rearrangement of 11

a) Generation of Si and B enolates


To a stirred solution of **11** (50 mg, 0.191 mmol, 1 eq) in 1 mL of dry DCM was added *N,N*-diisopropylethylamine (296 mg, 0.383 mmol, 12 eq, 0.761 mL, freshly distilled from sodium). The mixture was then cooled to -78°C and treated with appropriate triflate. After 0.5h, the reaction mixture was allowed to warm to ambient temperature and stirred for 3h. Dry methanol (492 mg, 15.383 mmol, 6 eq, 0.623 mL) was added followed by O-benzotriazole-*N,N,N',N'*-tetramethyl-uronium-hexafluoro-phosphate (2.917 g, 7.692 mmol, 3 eq) and 1-hydroxybenzotriazole hydrate (1.177 g, 7.692 mmol, 3 eq). The obtained mixture was stirred for 16 h, then diluted with saturated aqueous sodium bicarbonate solution, and extracted twice with DCM. The combined organic layers were dried over anhydrous Na₂SO₄, filtered and

concentrated *in vacuo*. The residue was purified by preparative HPLC/MS (MeOH : H₂O +1% HCOOH). The obtained results are shown in Table 1.

b) Generation of Zn enolate

A solution of **11** (60 mg, 0.230 mmol, 1 eq) was dropwise added to 1M LiHMDS solution in THF/ethylbenzene (77mg, 0.459 mmol, 2 eq, 0.459 mL). After stirring for 0.5h at -78°C, 1M ZnCl₂ in Et₂O (47 mg, 0.344 mmol, 1.5 eq, 0.344 mL) was added and the reaction mixture turned red. After 0.5h, the reaction mixture was allowed to warm to ambient temperature and was stirred for 3h. Formation of the intermediate carboxylic acid was not observed by LC/MS.


(*S,E*)-Methyl 4-ethylidene-1-(4-methoxybenzyl)pyrrolidine-2-carboxylate **14**



To a stirred solution of **11** (670 mg, 2.564 mmol, 1 eq) in 3 mL of dry DCM was added *N,N*-diisopropylethylamine (3.976 g, 30.767 mmol, 12 eq, 5.098 mL, freshly distilled from sodium). The mixture was then cooled to -78°C and 1M solution of dibutylboranylium trifluoromethanesulfonate (2.108 g, 7.692 mmol, 3 eq, 7.69 mL) in DCM was added dropwise. After 15 min the mixture was warmed to 10°C and stirred for 1h. Dry methanol (492 mg, 15.383 mmol, 6 eq, 0.623 mL) was then added, followed by O-benzotriazole-*N,N,N',N'*-tetramethyl-uronium-hexafluoro-phosphate (2.917 g, 7.692 mmol, 3 eq) and 1-hydroxybenzotriazole hydrate (1.177 g, 7.692 mmol, 3 eq). The obtained mixture was stirred for 16 h and then diluted with saturated aqueous sodium bicarbonate solution, and extracted twice with DCM. The combined organic layers were dried over anhydrous Na₂SO₄, filtered and concentrated *in vacuo*. The residue was purified by flash column chromatography (Pet:EtOAc 9:1 + 2% Et₃N). The title compound was isolated as a yellow oil (540 mg, 85%). ¹H NMR (400MHz; CDCl₃): δ 7.24 (2H, d, *J*=8.2), 6.83 (2H, d, *J*=8.2), 5.28 (1H, m), 3.84 (1H, d, *J*=12.5 Hz), 3.78 (3H, s), 3.69 (3H, s), 3.51 (1H, d, *J*=12.5 Hz), 3.41 (1H, d, *J*=12.5 Hz), 3.36 (1H, t, *J*=8.2 Hz), 2.98 (1H, d, *J*=12.5 Hz), 2.73 (1H, dd, *J*=16.3, 7.8 Hz), 2.53 (1H, dd, *J*=16.3, 7.8 Hz), 1.54 (3H, d, *J*=7.0 Hz). ¹³C NMR (100MHz, CDCl₃): δ 173.79, 158.77, 135.92, 130.31, 130.03, 115.53, 113.55, 65.44, 57.95, 57.91, 55.21, 51.78, 33.03, 14.30.


HRMS-ESI (m/z): [M + H] calculated for C₁₆H₂₂NO₃, 276.1660; found 276.1664. **IR** (ν_{max} , film): 2951, 2832, 1748, 1612, 1513, 1248, 1172. **[α]_D²⁵** = -56.29° (c = 0.75, CH₂Cl₂).

(*S,E*)-Methyl 4-ethylidenepyrrolidine-2-carboxylate hydrochloride SI-2



To a solution of **14** (250 mg, 0.908 mmol, 1 eq) in dry DCM (0.6 mL) was slowly added 1-chloroethyl chloroformate (259 mg, 1.816 mmol, 2 eq) slowly at 0°C. The reaction mixture was stirred for 20 min at 0°C. After removal of the solvent, the residue was dissolved in MeOH (1 mL) and refluxed for 40 min. Removal of the solvent and trituration with ether afforded a dark red oil which was used in the next step without further purification.


(*S,E*)-Methyl 4-ethylidene-1-(4-hydroxy-3-methoxybenzoyl)pyrrolidine-2-carboxylate SI-3



To a stirred slurry of vanillic acid (91 mg, 0.545 mmol, 1.5 eq) and benzotriazol-1-yloxy-tris(dimethylamino)-phosphonium hexafluorophosphate (240 mg, 0.545 mmol, 1.5 eq) in 3 mL of dry THF was added DIPEA (140 mg, 1.089 mmol, 3 eq). After stirring for 0.5h at ambient temperature, a solution of **SI-2** (69 mg, 0.363 mmol, 1 eq) in 1mL of dry THF was added. The obtained mixture was stirred for 16 h, then diluted with saturated aqueous sodium bicarbonate solution, and extracted twice with DCM. The combined organic layers were dried over anhydrous Na₂SO₄, filtered and concentrated *in vacuo*. The residue was purified by preparative HPLC/MS (MeOH : H₂O +1% HCOOH). The title compound was isolated as a yellow solid (46 mg, 41%). **¹H NMR** (400MHz; CDCl₃): δ 7.01 (1H, bm), 6.89 (1H, d, *J*=7.8 Hz), 5.98 (1H, s), 5.37 (0.5H, bs), 4.95 (0.5H, bs), 4.11 – 4.31 (2H, m), 3.89 (3H, s), 3.76 (3H, bs), 2.85 – 2.93 (1H, m), 2.64 – 2.69 (1H, m), 1.61 (3H, d, *J*=6.65 Hz). **¹³C NMR** (100MHz,

CDCl₃): δ 172.61, 169.76, 147.70, 146.45, 134.15, 127.52, 120.96, 117.78, 113.79, 110.64, 58.58, 55.97, 54.05, 52.32, 30.91, 14.34. **HRMS-ESI** (m/z): [M + Na] calculated for C₁₆H₁₉NO₅Na, 328.1161; found 328.1184. $[\alpha]_D^{25} = -19.44^\circ$ (c = 0.25, CH₂Cl₂).

Barmumycin 1




A solution of ester **SI-3** (10 mg, 0.033 mmol, 1 eq) in dry THF (0.5 mL) was cooled to 0°C and treated portion-wise with LiBH₄ (2 mg, 0.098 mmol, 3 eq). The stirred reaction mixture was allowed to warm to room temperature over 2.5 h, after which the TLC revealed complete consumption of the starting material. The mixture was cooled to 0°C, treated with water and extracted twice with DCM. The combined organic layers were dried over anhydrous Na₂SO₄, filtered and concentrated *in vacuo*. The residue was purified by preparative HPLC/MS (MeOH : H₂O +1% HCOOH). The title compound was isolated as a yellow solid (6.1 mg, 71%). **¹H NMR** (400MHz; CDCl₃): δ 7.09 (1H, s), 7.04 (1H, d, *J*=7.82 Hz), 6.91 (1H, d, *J*=7.82 Hz), 5.92 (1H, bs), 5.36 (1H, bs), 4.66 (1H, bs), 4.06 – 4.20 (2H, m), 3.91 (3H, s), 3.74 (2H, bs), 2.68 – 2.76 (1H, m); 2.22 – 2.32 (1H, m), 1.62 (3H, d, *J*=6.65 Hz). **¹³C NMR** (100MHz, CDCl₃): δ 171.71, 147.53, 146.43, 134.44, 128.07, 120.76, 117.39, 113.81, 110.35, 67.01, 60.41, 56.07, 54.96, 30.04, 14.33. **HRMS-ESI** (m/z): [M + H] calculated for C₁₅H₂₀NO₄, 278.1387; found 278.1386. $[\alpha]_D^{25}$ Lit. -51.2° (c = 0.25, CH₂Cl₂); found -49.6° (c = 0.25, CH₂Cl₂).

Comparison of Barmumycin to the literature NMR data

δ_{H} , (400MHz; CDCl ₃)	Lit. δ_{H} , (400MHz; CDCl ₃)	δ_{C}	Lit. δ_{C}
1.62 (3H, d, $J=6.65$ Hz)	1.62 (3H, d, $J=6.8$ Hz)	14.33	14.5
2.22 – 2.32 (1H, m)	2.20-2.35 (1H, m)	30.04	30.1
2.68 – 2.76 (1H, m)	2.67-2.77 (1H, m)	54.96	55.1
3.74 (2H, bs)	3.75 (2H, bs)	56.07	56.3
3.91 (3H, s)	3.90 (3H, s)	60.41	60.6
4.02 – 4.20 (2H, m)	4.00-4.22 (2H, m)	67.01	67.1
4.66 (1H, bs)	4.67 (1H, bs)	110.35	110.6
5.36 (1H, bs)	5.34 (1H, bs)	113.81	114.1
5.92 (1H, bs)	-	117.39	117.6
6.91 (1H, d, $J=7.82$ Hz)	6.91 (1H, d, $J=7.8$ Hz)	120.76	121.0
7.04 (1H, d, $J=7.82$ Hz)	7.04 (1H, d, $J=7.82$ Hz)	128.07	128.3
7.09 (1H, s)	7.09 (1H, s)	134.44	134.7
		146.43	146.7
		147.53	147.8
		171.71	172.0

Methyl 2-amino-3-hydroxy-4-methoxybenzoate SI-4



To a stirred solution of methyl 3-hydroxy-4-methoxy-2-nitrobenzoate¹ (6.60 mmol, 1.500 g) in 20 mL of EtOH was added 50 mg of 10% Pd on carbon and the reaction flask was then purged with hydrogen (balloon) three times and the reaction was stirred for 14 h at room temperature. The catalyst was filtered off, the solvent was evaporated and the residue was purified by flash column chromatography (Pet:EtOAc 3:1). The title compound was isolated as a yellow solid (1.350 g, 90%). ¹H NMR (400MHz; CDCl₃): δ 7.47 (1H, d, $J=8.9$ Hz), 6.28 (1H, d, $J=8.9$ Hz), 5.77 (2H br s), 5.44 (1H, br s), 3.89 (3H, s), 3.84 (3H, s). ¹³C NMR


¹ WO 2008/006050

(100MHz, CDCl₃): δ 168.28, 148.86, 139.63, 131.47, 123.04, 105.85, 99.509, 55.946, 51.31. **HRMS-ESI** (m/z): [M + H] calculated for C₉H₁₂NO₄, 198.0766; found 198.0775. **IR**: (ν_{\max} , film): 3425, 3333, 2902, 1658, 1464, 1377, 1278, 1214, 1088 cm⁻¹. **M.p.** 70–72°C. Characterization Data matches that reported in the literature².

Comparison of SI-4 to the literature NMR data

δ_{H} , (400MHz; CDCl ₃)	Lit. δ_{H} , (300MHz; CDCl ₃)	δ_{C}	Lit. δ_{C}
3.84 (3H, s)	3.85 (3H, s)	51.31	51.6
3.89 (3H, s)	3.91 (3H, s)	55.946	56.2
5.44 (1H, br s)	-	99.509	99.7
5.77 (2H br s)	5.72 (2H br s, H/D)	105.85	106.1
6.28 (1H, d, $J=8.9$ Hz)	6.29 (1H, d, $J=9.0$ Hz)	123.04	123.3
7.47 (1H, d, $J=8.9$ Hz)	7.47 (1H, d, $J=9.0$ Hz)	131.47	131.7
		139.63	139.9
		148.86	149.1
		168.28	168.6

2-Amino-3-hydroxy-4-methoxybenzoic acid SI-5




To a stirred solution of **SI-4** (380 mg, 1.927 mmol, 1 eq) was dropwise added 2.89 mL of 1M boron tribromide solution (724 mg, 2.891 mmol, 1.5 eq) at -78°C. The mixture was warmed to ambient temperature overnight. Water (~1 mL) was then added and after 0.5 h of stirring, the mixture was evaporated to dryness. The residue was purified on reversed phase flash chromatography (MeOH:H₂O + 1% AcOH). The title compound was isolated as a grey solid (200 mg, 57%).

¹H NMR (400MHz; (CH₃)₂SO): δ 8.48 (1H br s), 7.28 (1H, d, $J=8.9$ Hz), 6.31 (1H, d, $J=8.9$ Hz), 3.79 (3H, s), 3.33 (2H, br s). **¹³C NMR** (100MHz, (CH₃)₂SO): δ 169.42, 149.91, 141.54,

² Fotso, S.; Zabriskie, T., M.; Proteau, P., J.; Flatt, P., M.; Santosa, D., A.; Mahmud, S.; Mahmud, T. *J. Nat. Prod.* **2009**, 72, 690-695


131.31, 122.51, 104.80, 99.79, 55.56. **HRMS-ESI** (m/z): [M + H] calculated for C₈H₁₀NO₄, 184.0610; found 184.0636. **IR**: (v_{max}, film) 3491, 3378, 2951, 1683, 1625, 1272, 1120 cm⁻¹. **M.p.** 190°C (dec.).

(*S,E*)-2-Ethylidene-9-hydroxy-8-methoxy-2,3-dihydro-1*H*-benzo[*e*]pyrrolo[1,2-*a*][1,4]diazepine-5,11(10*H*,11*aH*)-dione 17




To a stirred solution of **SI-2** (208 mg, 1.090 mmol, 1 eq), **SI-5** (400 mg, 2.180 mmol, 2 eq), benzotriazol-1-yloxy-tris(dimethylamino)-phosphonium hexafluorophosphate (965 mg, 2.180 mmol, 2 eq) and 1-hydroxybenzotriazole hydrate (334 mg, 2.180 mmol, 2 eq) in 10 mL of *N,N*-dimethylformamide was added triethylamine (550 mg, 5.45 mmol, 5 eq) and the obtained solution was stirred for 16 h. The volatiles were removed *in vacuo* and the residue was partitioned between DCM and brine. The organic phase was dried over anhydrous Na₂SO₄, filtered and concentrated *in vacuo*. The residue was purified by flash column chromatography (MeOH:CHCl₃ 1:20). The collected product was recrystallized from acetonitrile. The title compound was isolated as a white solid (200 mg, 64%). **¹H NMR** (400MHz; CD₃OD): δ 7.39 (1H, d, *J*=8.9 Hz), 6.91 (1H, d, *J*=8.9 Hz), 5.55 (1H, m), 4.33 (2H, d, *J*=11.3 Hz), 4.11 (1H, d, *J*=16.4 Hz), 3.94 (3H, s), 3.46 (1H, d, *J*=16.4 Hz), 2.69 (1H, dd, *J*=16.4, 9.7 Hz), 1.74 (3H, d, *J*=6.6 Hz). **¹³C NMR** (100MHz, CD₃OD + few drops of CDCl₃): δ 170.39, 166.49, 150.17, 136.08, 132.88, 124.51, 120.71, 119.58, 117.79, 107.63, 57.20, 55.50, 51.21, 27.00, 13.43. **HRMS-ESI** (m/z): [M + H] calculated for C₁₅H₁₇N₂O₄, 289.1188; found 289.1198. **IR** (v_{max}, film): 3373, 3244, 2928, 2840, 1699, 1626, 1585, 1435, 1383, 1259, 1177. [α]_D²⁵=280.83°(c = 0.1, MeOH); **M.p.** 230°C (dec.).

(9*aS,E*)-8-Ethylidene-3-methoxy-1-phenyl-7,8,9*a*-tetrahydro-1*H*-2-oxa-6*a*,10*a*-diazabenz[*cd*]cyclopenta[*g*]azulene-6,10-dione 18



To solid **17** (100 mg, 0.347 mmol, 1 eq) was added 1mL of benzaldehyde dimethyl acetal and *p*-toluenesulfonic acid hydrate (6 mg, 0.035 mmol, 0.1 eq) and the obtained mixture was heated to reflux at 150°C for 8 h. After that the mixture was directly purified by flash column chromatography (Pet:EtOAc 2:1). The title compound was isolated as a yellow solid (80 mg, 61%). **¹H NMR** (400MHz; CDCl₃): δ 7.59 (1H, d, *J*=8.9 Hz), 7.43 (2H, m), 7.35 (3H, m), 7.32 (1H, s), 6.84 (1H, d, *J*=8.9 Hz), 5.51 (1H, m), 4.51 (1H, d, *J*=15.6 Hz), 4.32 (1H, d, *J*=15.6 Hz), 4.06 (1H, d, *J*=15.6 Hz), 3.97 (3H, s), 3.56 (1H, d, *J*=15.6 Hz), 2.73 (1H, dd, *J*=15.6, 9.7 Hz), 1.72 (3H, d, *J*=7.0 Hz). **¹³C NMR** (100MHz, CDCl₃): δ 169.33, 165.20, 146.46, 137.59, 136.41, 132.20, 129.85, 128.76, 128.34, 125.84, 123.47, 118.44, 114.41, 110.67, 95.20, 59.00, 56.63, 52.11, 28.14, 14.48. **HRMS-ESI** (*m/z*): [*M* + *H*] calculated for C₂₂H₂₁N₂O₄, 377.1501; found 377.1505.

Limazepine E 4




To a stirred solution of **18** (65 mg, 0.173 mmol, 1 eq) in 3 mL of dry methanol was added sodium borohydride (20 mg, 0.518 mmol, 3 eq) at 0°C. The mixture was then warmed to ambient temperature and stirred for 3h, then diluted with saturated aqueous sodium bicarbonate solution, and extracted twice with DCM. The combined organic layers were dried over anhydrous Na₂SO₄, filtered and concentrated *in vacuo*. The residue was purified by preparative HPLC/MS (MeOH : H₂O +1% HCOOH). The collected aqueous fractions were basified with saturated aqueous sodium bicarbonate solution, and extracted with DCM. The combined organic layers were dried over anhydrous Na₂SO₄, filtered and concentrated *in vacuo*. The title compound was isolated as a yellow solid. (6 mg, 13%). **¹H NMR** (600MHz; CDCl₃): δ 7.78 (1H, d, *J*=4.2 Hz), 7.61 (1H, d, *J*=9.0 Hz), 6.94 (1H, d, *J*=9.0 Hz), 5.60 (1H,

m), 4.25 (2H, AB m), 3.96 (3H, s), 3.96 (1H, m), 2.98 (2H, d, $J=5.5$ Hz), 1.74 (3H, d, $J=6.8$ Hz). ^{13}C NMR (125MHz, CDCl_3): 165.48, 164.63, 148.84, 140.18, 132.77, 132.57, 121.65, 120.80, 119.01, 110.81, 56.22, 54.25, 51.69, 31.22, 14.60. HRMS-ESI (m/z): $[\text{M} + \text{H}]$ calculated for $\text{C}_{15}\text{H}_{17}\text{N}_2\text{O}_3$, 273.1239; found 243.1256. $[\alpha]_{\text{D}}^{25} = 232.41^\circ$ ($c = 0.58$, CHCl_3). Characterization Data matches that reported in the literature.

Comparison of natural and synthetic Limazepine E NMR data


δ_{H} , (600MHz; CDCl_3)	Lit. δ_{H} , (400MHz; CDCl_3)	δ_{C}	Lit. δ_{C}
1.74 (3H, d, $J=6.8$ Hz)	1.76 (3H, d, $J=6.8$ Hz)	14.60	14.8
2.98 (2H, d, $J=5.5$ Hz)	3.00 (2H, br d, $J=5.8$ Hz)	31.22	31.5
3.96 (1H, m)	3.98 (1H, m)	51.69	51.9
3.96 (3H, s)	3.98 (3H, s)	54.25	54.5
4.25 (2H, AB m)	4.28 (2H, br s)	56.22	56.5
5.60 (1H, m)	5.62 (1H, m)	110.81	111.1
6.94 (1H, d, $J=9.0$ Hz)	6.97 (1H, d, $J=8.9$ Hz)	119.01	119.2
7.61 (1H, d, $J=9.0$ Hz)	7.63 (1H, d, $J=8.9$ Hz)	120.80	121.0
7.78 (1H, d, $J=4.2$ Hz)	7.80 (1H, d, $J=4.3$ Hz)	121.65	121.9
		132.57	132.0
		132.77	132.8
		140.18	140.4
		148.84	149.1
		164.63	164.9
		165.48	165.7

(*S,E*)-2-Ethylidene-2,3-dihydro-1*H*-benzo[*e*]pyrrolo[1,2-*a*][1,4]diazepine-5,11(10*H*,11*aH*)-dione 19



The title compound was obtained similarly as described for preparation of **17**. White solid (70mg, 41%) was obtained. **¹H NMR** (400MHz; CD₃OD): δ 7.86 (1H, d, *J*=7.82 Hz), 7.54 (1H, t, *J*=7.82 Hz), 7.28 (1H, t, *J*=7.82 Hz), 7.13 (1H, d, *J*=7.82 Hz), 5.56 (1H, m), 4.35 (1H, dd, *J*=9.39, 2.35 Hz), 4.31 (1H, m), 4.12 (1H, d, *J*=16.04Hz), 3.44 (1H, d, *J*=16.04Hz), 2.69 (1H, m), 1.74 (3H, d, *J*=6.65). **¹³C NMR** (100MHz, CD₃OD): δ 170.76, 166.27, 136.35, 133.04, 132.44, 129.92, 126.27, 124.35, 121.09, 117.61, 56.94, 51.07, 26.80, 13.09. **IR** (ν_{max}, film): 3292, 2923, 2854, 1694, 1668, 1637, 1629, 1603, 1591, 1476, 1413, 1249, 1167. **HRMS-ESI** (m/z): [M + H] calculated for C₁₄H₁₅N₂O₂, 243.1134; found 243.1135. [α]_D²⁵ = 553.60° (c = 0.1, MeOH). **M.p.** 245°C (dec.).

(S)-1H-Benzo[e]pyrrolo[1,2-a][1,4]diazepine-2,5,11(3H,10H,11aH)-trione **20**





Ozone was bubbled through a solution of **19** (50 mg, 0.206 mmol, 1 eq) in dry dichloromethane at -78°C until the mixture remained blue. Then oxygen was bubbled through the mixture to remove the excess of ozone, after which polymer-supported triphenylphosphine (1.4-2.0 mmol/g, 370 mg, ~0.6 mmol, ~3 eq) was added. The mixture was then warmed to ambient temperature overnight. The resin was filtered off, the mixture was concentrated *in vacuo* and the residue was purified by flash column chromatography (MeOH:CHCl₃ 1:20). The title compound was isolated as a white solid (35 mg, 74%). Characterization Data matches that reported in the literature. **¹H NMR** (400MHz; CDCl₃): δ 8.12 (1H, s), 8.00 (1H, d, *J*=7.8 Hz), 7.55 (1H, t, *J*=7.8 Hz), 7.33 (1H, t, *J*=7.8 Hz), 7.04 (1H, d, *J*=7.8 Hz), 4.59 (1H, dd, *J*=13.7, 3.5 Hz), 4.30 (1H, d, *J*=19.9 Hz), 3.95 (1H, d, *J*=19.9 Hz), 3.60 (1H, d, *J*=19.9 Hz), 2.82 (1H, dd, *J*=19.6, 10.2 Hz). **¹³C NMR** (100MHz, CDCl₃): δ 206.46, 169.31, 166.02, 134.82, 133.20, 131.44, 125.90, 121.23, 53.98, 52.76, 36.64. **IR** (ν_{max}, film): 3229, 2920, 1772, 1696, 1616, 1483, 1454, 1384, 1254, 1165. **HRMS-ESI** (m/z): [M + H] calculated for C₁₂H₁₃N₂O₃, 233.0926; found 233.0931. [α]_D²⁵ Lit. 548° (c = 0.124, MeOH); found 550.81° (c = 0.124, MeOH). **M.p.** 202-204°C.

Comparison of 20 to the literature NMR data

δ_{H} , (400MHz; CDCl ₃)	Lit. δ_{H} , (400MHz; CDCl ₃)	δ_{C}	Lit. δ_{C}
2.84 (1H, dd, $J=19.4$, 10.2 Hz)	2.82 (1H, dd, $J=19.6$, 10.2 Hz)	36.64	36.6
3.62 (1H, dd, $J=19.5$, 3.5 Hz)	3.60 (1H, dd, $J=19.9$, 3.5 Hz)	52.76	52.8
3.95 (1H, d, $J=20.2$ Hz)	3.95 (1H, d, $J=19.9$ Hz)	53.98	54.0
4.30 (1H, d, $J=20.2$ Hz)	4.30 (1H, d, $J=19.9$ Hz)	121.23	121.3
4.61 (1H, dd, $J=10.2$, 3.5 Hz)	4.59 (1H, dd, $J=13.7$, 3.5 Hz)	125.90	125.88
7.08 (1H, d, $J=8.1$ Hz)	7.04 (1H, d, $J=7.8$ Hz)		125.90
7.34 (1H, t, $J=7.8$ Hz)	7.33 (1H, t, $J=7.8$ Hz)	131.44	131.4
7.56 (1H, t, $J=8.0$ Hz)	7.55 (1H, t, $J=7.8$ Hz)	133.20	133.2
8.01 (1H, d, $J=7.9$ Hz)	8.00 (1H, d, $J=7.8$ Hz)	134.82	134.9
8.60 (1H, br s)	8.12 (1H, s)	166.02	166.1
		169.31	169.5
		206.46	206.5

NMR spectra






7.219
7.199
6.869
6.848


5.395
5.120
5.032
5.015


3.831
3.798
3.608
3.596
3.575
3.556
3.530
3.497
3.449
3.414
3.384
3.349

1.551
1.535





¹H in CDCl₃ at 400MHz






^{13}C at 100MHz in CDCl_3







7.130
7.101
6.907
6.888

5.978


5.376

4.956


4.313
4.278
4.148
3.890
3.763


2.918
2.881
2.857
2.686
2.647


1.626
1.609





^1H in CDCl_3 at 400MHz






































Comparison of natural and synthetic Limazepine E ^1H NMR

